Epizyme (EPZM) said Tuesday it closed two concurrent underwritten public offerings of 11.5 million shares of its common stock and 350,000 shares of its...
Epizyme (EPZM) on Thursday priced its two concurrent underwritten public offerings of 10 million shares of its common stock and 304,348 shares of its...
Epizyme (EPZM) said on Wednesday it plans to sell shares and Series A convertible preferred stock in two concurrent but separate underwritten public...
Epizyme (EPZM) said Friday in a form 8-K filing with the Securities and Exchange Commission that it has reopened the enrollment of patients in France for...
| Address | 400 Technology Square Cambridge, Massachusetts 02139 |
| Phone | +1.617.229.5872 |
| Number of Employees | 124 |
| Recent SEC Filing | 05/22/2019 CT ORDER |
| President, Chief Executive Officer & Director | Robert B. Bazemore |
| Principal Financial Officer | Matthew E. Ros |
| Chief Medical Officer | Shefali Agarwal |
| Vice President-Business Development | Michael Boretti |
| Price Open | $12.55 |
| Previous Close | $12.93 |
| 52 Week Range | $5.14 - 18.70 |
| Market Capitalization | $1.2 B |
| Shares Outstanding | 90.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/01/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.64 |
| Beta vs. S&P 500 | N/A |
| Revenue | $21.7 M |
| Net Profit Margin | -401.82% |
| Return on Equity | -48.59% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
